H.I.G. Capital, a leading global alternative investment firm with $70 billion of capital under management, is pleased to announce that its portfolio company, Highridge Medical, has completed the sale of its EBI Bone Healing Division to Avista Healthcare Partners. H.I.G. continues to own Highridge, a leader in the global spinal device market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies. The divestiture marks a strategic move by Highridge to prioritize its focus on core spine solutions and accelerate innovation in surgical technologies.
Health Technology Insights: Qbtech Grows US Operations with New Houston Teams
H.I.G. initially acquired EBI as part of the Highridge take-private transaction in April 2024. Based in Parsippany, NJ, EBI is a leading provider of non-invasive bone stimulation devices for spinal and orthopedic patients. Following the acquisition, H.I.G. made several significant investments in EBI, including the addition of new senior leadership and expanded product development capabilities.
Glen Kashuba, CEO of EBI, commented: “I’m incredibly proud of the EBI team and all that we’ve accomplished together. This next chapter presents an exciting opportunity to broaden the Company’s impact by delivering proven bone healing technologies to even more patients. EBI remains deeply committed to advancing care, supporting our clinical partners, and driving meaningful, life-changing outcomes.”
Health Technology Insights: Dr. Ray Kotwicki Named President of Southern Psychiatric Association
Mike Gallagher, Managing Director at H.I.G., added: “We have had a successful partnership with Glen and his team to support the growing demand for EBI’s product line. Their team brings deep sector expertise and a strong track record of successful commercial execution, innovation, and advancing patient care. EBI is in excellent hands going forward and well-positioned for continued success. Furthermore, this transaction allows us to make significant investments in Highridge’s core spine business, where we see tremendous opportunities to lead the next generation of spine care through continued focus on innovation and exceptional patient outcomes.”
Robert W. Baird & Co. acted as financial advisor and McDermott Will & Emery LLP served as legal advisor to H.I.G. in connection with the transaction.
Health Technology Insights: BlueRidge Life Sciences Appoints Ian Kelly as Chief Executive Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
